Cargando…
Targeting Hepatocellular Carcinoma: What did we Discover so Far?
Hepatocellular carcinoma (HCC) is increasingly considered an issue of global importance. Its rates of incidence and mortality have been markedly increasing over the last decades. Among risk factors, some should be highlighted, namely the infections by hepatitis B and C virus, as well as clinical cas...
Autores principales: | Brito, Ana Filipa, Abrantes, Ana Margarida, Tralhão, José Guilherme, Botelho, Maria Filomena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136756/ https://www.ncbi.nlm.nih.gov/pubmed/27994769 http://dx.doi.org/10.4081/oncol.2016.302 |
Ejemplares similares
-
Folate Metabolism in Hepatocellular Carcinoma. What Do We Know So Far?
por: Quevedo-Ocampo, Jaqueline, et al.
Publicado: (2022) -
The role of mouse models in colorectal cancer research—The need and the importance of the orthotopic models
por: Oliveira, Rui C., et al.
Publicado: (2020) -
What we know so far
Publicado: (2021) -
Anabaenopeptins: What We Know So Far
por: Monteiro, Patrick Romano, et al.
Publicado: (2021) -
FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?
por: Psilopatis, Iason, et al.
Publicado: (2023)